Myeloproliferative Neoplasm

AVID200 led to significant reduction in serum transforming growth factor beta levels and improved platelet counts among patients with advanced myelofibrosis, according to study results presented at ASH Annual Meeting and Exposition.

Nearly one in six patients with hematologic disorders had a negative COVID-19 vaccination-related antibody response, according to results of a prospective, observational single-center study presented at ASH Annual Meeting and Exposition.

The FDA approved ropeginterferon alfa-2b-njft for the treatment of adults with polycythemia vera.

Three individuals have been elected to American Society of Hematology’s executive committee.

American Association for Cancer Research urged the CDC to expand availability of COVID-19 booster vaccinations to caregivers and other individuals who share a home with patients with cancer.

September is Blood Cancer Awareness Month.

Lachelle Dawn Weeks, MD, PhD, of Dana-Farber Cancer Institute and Emilio Ramos, MD, PhD, of University of California, San Francisco, received the ASH-Harold Amos Medical Faculty Development Program Award.

Approximately one-quarter of patients with hematologic malignancies did not produce measurable antibodies after two doses of COVID-19 vaccines, according to a study from The Leukemia & Lymphoma Society published in Cancer Cell.

The FDA granted breakthrough therapy designation to venetoclax in combination with azacitidine for treatment of certain patients with myelodysplastic syndrome.

The Leukemia & Lymphoma Society’s therapy acceleration program announced five investments intended to hasten development of immunotherapies to treat blood cancers.